Cargando…

Recommendations for the treatment of hepatitis B in 2017

The therapeutic goal which is currently unfrequent but realistic in HBV infected patients is sustained HBsAg clearance. It is preceded by the loss or significant suppression of HBV replication and leads to inhibition of the progression of liver fibrosis, normalization of biochemical indicators of li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flisiak, Robert, Halota, Waldemar, Jaroszewicz, Jerzy, Juszczyk, Jacek, Małkowski, Piotr, Pawłowska, Małgorzata, Piekarska, Anna, Simon, Krzysztof, Tomasiewicz, Krzysztof, Wawrzynowicz-Syczewska, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497479/ https://www.ncbi.nlm.nih.gov/pubmed/28856289 http://dx.doi.org/10.5114/ceh.2017.67626

Ejemplares similares

Recommendations for the treatment of hepatitis C in 2017
por: Halota, Waldemar, et al.
Publicado: (2017)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020
por: Halota, Waldemar, et al.
Publicado: (2020)

Recommendations for treatment of hepatitis C. Polish Group of HCV Experts – 2015
por: Halota, Waldemar, et al.
Publicado: (2015)

Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016
por: Halota, Waldemar, et al.
Publicado: (2016)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Distribution of HBV genotypes in Poland
por: Świderska, Magdalena, et al.
Publicado: (2015)

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation
por: Pawłowska, Małgorzata, et al.
Publicado: (2019)

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C
por: Domagalski, Krzysztof, et al.
Publicado: (2015)

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021)

Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus
por: Domagalski, Krzysztof, et al.
Publicado: (2016)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

Prevalence of hepatitis delta infections among HBs-antigen-positive inhabitants of southeastern and northwestern parts of Poland
por: Pleśniak, Robert, et al.
Publicado: (2019)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection
por: Pawlowska, Malgorzata, et al.
Publicado: (2011)

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
por: Jaroszewicz, Jerzy, et al.
Publicado: (2022)

Vertical genotype 1 HCV infection treated successfully in the second year of life: A case report
por: Pawłowska, Małgorzata, et al.
Publicado: (2012)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Characteristic features of ulcerative colitis with concomitant primary sclerosing cholangitis
por: Uździcki, Artur W., et al.
Publicado: (2021)

Distribution of HCV Genotypes in the Populations of Inmates in Polish Prison Potulice and Patients Hospitalised in Bydgoszcz
por: Tyczyno, Malgorzata, et al.
Publicado: (2014)

Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents – A Longitudinal Study in Real Life
por: Pawłowska, Małgorzata, et al.
Publicado: (2016)

Effect of hepatitis B virus (HBV) infection on the course of pregnancy and newborns’ health status
por: Łapiński, Tadeusz Wojciech, et al.
Publicado: (2015)

Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2015)

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
por: Domagalski, Krzysztof, et al.
Publicado: (2013)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Normalizing serum hepcidin but not α-1-antitrypsin level during effective treatment of chronic hepatitis C
por: Rogalska-Taranta, Magdalena, et al.
Publicado: (2017)

Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review
por: Rzymski, Piotr, et al.
Publicado: (2023)

Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland
por: Leszczyszyn-Pynka, Magdalena, et al.
Publicado: (2016)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
por: Flisiak, Robert, et al.
Publicado: (2021)

Late Recurrence of Hepatocellular Carcinoma in a Patient 10 Years after Liver Transplantation Unrelated to Transplanted Organ
por: Morisson-Sarapak, Kornelia, et al.
Publicado: (2021)

Acute hepatitis A virus infection in patients hospitalized at the Department of Infectious Diseases, Medical University of Lublin (Eastern Poland) in 2017 – a hospital-based retrospective study
por: Krzowska-Firych, Joanna Małgorzata, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dr8hkkofni03a9pp43dqj30eak